John D. Chovan, James R. Cacchillo
Seizures, Patient Outcomes
Medical Pathology | Medicine and Health Sciences | Nervous System Diseases | Nursing
Juvenile myoclonic epilepsy (JME) is one of the most common epilepsies of childhood (Korff, Nordli, & Eichler, 2014). JME typically occurs in otherwise healthy teenagers, and is characterized by one or more of the following seizure types: myoclonic jerks, generalized tonic clonic seizures, and absence seizures (Korff, Nordli, & Eichler, 2014). JME is thought to have genetically mediated factors (Park, Shahid, & Jammoul, 2015). JME is considered to be gender equal (Korff, Nordli, & Eichler, 2014). Most JME patients are diagnosed between 12 and 18 years of age (Korff, Nordli, & Eichler, 2014). Triggers linked to onset of seizure activity include: sleep deprivation, fatigue, alcohol, mental stress, and flashing lights (Park, Shahid, & Jammoul, 2015). Although the frequency of seizures typically decreases as the individual progresses through adulthood, JME is usually a life-long disease (Korff, Nordli, & Eichler, 2014). The majority of patients with JME respond to antiepileptic treatment, and are able to live free from seizure, as long as they maintain treatment (Afra & Adamolekun, 2011). However, antiepileptic medication can have adverse effects, possibly leading to poor tolerance, and compliance with treatment (Afra & Adamolekun, 2011). Education of JME patients and their families, by their healthcare provider, on disease and treatment (including non-pharmacological treatment such as life-style modification) is essential for disease management, and improved patient outcomes.
Britton, April, "Juvenile Myoclonic Epilepsy" (2015). Master of Science in Nursing (MSN) Student Scholarship. Paper 76.